CoChat

Post‐infectious irritable bowel syndrome (PI‐IBS) after infection with Shiga‐like toxin‐producing Escherichia coli (STEC) O104:H4: A cohort study with prospective follow‐up

Open access
Andresen, Viola, Löwe, Bernd, Broicher, Wiebke, Riegel, Björn, Fraedrich, Katharina, von Wulffen, Moritz, Gappmayer, Kerrin, Wegscheider, Karl, Treszl, András, Rose, Matthias, Layer, Peter, Lohse, Ansgar W · 2016 · United European Gastroenterology Journal
Cited by 38

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Background: In May/June 2011, the new Shiga‐like toxin‐producing Escherichia coli (STEC) strain O104:H4 caused the severest outbreak ever recorded of hemorrhagic enterocolitis in 3842 patients in Germany. Objectives: As bacterial enterocolitis is an established risk factor of subsequent irritable bowel syndrome (IBS), we aimed to estimate prevalence and incidence of post‐infectious (PI)‐IBS after six and 12 months in a cohort of STEC O104:H4 patients and to prospectively identify associated somatic and psychometric risk factors. Methods: A total of 389 patients were studied prospectively at baseline and at six and 12 months after STEC infection using STEC disease‐related questionnaires and validated instruments for IBS (Rome III) and psychological factors. Frequencies and logistic regression models using multiple imputations were applied to assess predictor variables. Results: Prevalence of IBS increased from 9.8% prior to STEC infection to 23.6% at six and 25.3% at 12 months after STEC infection. In patients without IBS symptoms prior to STEC infection, incidence of new IBS was 16.9%. Logistic regression models indicated higher somatization and anxiety scores as risk factors for, and mesalazine treatment during, STEC infection as the only significant protective factor against IBS. No other factor analyzed, including disease severity, showed an association. Conclusions: PI‐IBS rates following this unusually severe STEC outbreak were similar to what has been observed after other infectious gastroenteritis outbreaks. Our findings suggest that mesalazine may have reduced the risk of subsequent PI‐IBS. As altered mucosal immune activity is a pivotal pathogenic factor in PI‐IBS, our observation of a potential protective effect of mesalazine might be explained by its known modulatory action on mucosal immunity, and may warrant further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2050640615581113

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 38

Metadata

Authors
Andresen, V., Löwe, B., Broicher, W., Riegel, B., Fraedrich, K., von Wulffen, M., Gappmayer, K., Wegscheider, K., Treszl, A., Rose, M., Layer, P., & Lohse, A. W.
Venue
United European Gastroenterology Journal
Publisher
Wiley
Published
2016-02
Volume
4
Issue
1
Pages
121-131
ISSN
  • 2050-6406 (ISSN-L)
  • 2050-6414
OpenAlex
W2029678437
Cited by
38
References
14
FWCI
4.77
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Post‐infectious irritable bowel syndrome (PI‐IBS) after infection with Shiga‐like toxin‐producing Escherichia coli (STEC) O104:H4: A cohort study with prospective follow‐up. https://app.cochat.ai/papers/10.1177/2050640615581113
The paper
Andresen, V., Löwe, B., Broicher, W., Riegel, B., Fraedrich, K., von Wulffen, M., Gappmayer, K., Wegscheider, K., Treszl, A., Rose, M., Layer, P., & Lohse, A. W. (2016). Post‐infectious irritable bowel syndrome (PI‐IBS) after infection with Shiga‐like toxin‐producing Escherichia coli (STEC) O104:H4: A cohort study with prospective follow‐up. United European Gastroenterology Journal. https://doi.org/10.1177/2050640615581113

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.